PNASEER

About PNASEER

Pnaseer Inc. is a South Korean biotechnology company founded in 2023 that specializes in developing advanced drug delivery technologies. The company, led by CEO Shin Hyunwoo, enhances the therapeutic performance of approved drugs by utilizing its proprietary bio-nanoparticle platform. Pnaseer's core technology is a one-step drug delivery system (DDS) that uses self-assembling hydrogels to simplify the drug manufacturing process. This system is designed to be versatile, applicable to various active pharmaceutical ingredients (APIs) like small molecules, peptides, antibodies, and RNA/DNA.

The company's platform, known as Encapsula™, uses self-assembling hyaluronic acid to create a porous hydrogel that encapsulates active ingredients. This technology is engineered to improve bioavailability, target specific tissues more effectively, and provide controlled release of therapeutics. It has applications in both injectable and topical formulations. The injectable platform is being explored for therapeutic areas such as oncology, neurology, and immunology, while the topical applications are aimed at dermatological and cosmeceutical products.

Pnaseer Inc. operates with a strategy of forming global partnerships and has established a sister company in the United Kingdom, PNAS Therapeutics Ltd., to concentrate on pharmaceuticals and address unmet medical needs. PNAS Therapeutics, co-founded by Dr. Shin Sung Min, is based in London and Oxford. A significant collaboration for Pnaseer is 'Project Follica,' a strategic partnership with Singapore-based NYB.AI. This project combines Pnaseer's drug delivery system with NYB.AI's artificial intelligence platform, which predicts compound-target interactions to accelerate the discovery of compounds for hair follicle regeneration. Pnaseer's role is to formulate delivery systems that maximize the bioavailability and targeting precision of promising candidates identified by the AI models.